REGN Investor Alert: Robbins Geller Rudman & Dowd LLP Announcement

If you purchased or acquired Regeneron Pharmaceuticals, Inc. (REGN) securities between February 17, 2017, and May 5, 2017, you may be eligible to become the lead plaintiff in a securities class action lawsuit against the company.

The Private Securities Litigation Reform Act of 1995 allows investors to take legal action if they believe they have been misled or suffered losses due to violations of federal securities laws. In this case, the lawsuit alleges that Regeneron made false and misleading statements about the company’s business prospects and financial performance during the specified time period.

To qualify as a lead plaintiff, you must meet certain criteria, including experiencing financial losses and actively participating in the lawsuit. By taking on this role, you can represent the class of investors who have been impacted by the alleged securities violations.

If you believe you may be eligible to serve as the lead plaintiff in this case, it is important to take prompt action. The deadline to apply for this position is fast approaching, so it is essential to consult with legal counsel as soon as possible to discuss your options and determine the best course of action.

By participating in the lead plaintiff process, you have the opportunity to seek justice for yourself and other investors who may have suffered losses as a result of Regeneron’s alleged misconduct. Remember, the deadline to apply for the lead plaintiff position is drawing near, so don’t delay in seeking legal guidance if you believe you may qualify for this role.